All News
Day 1 Report from ACR21
The first full day of Abstracts and Presentations from ACR Convergence, was full of highly engaging sessions, quality posters and unique presentations. To hear more about the best of the best, I would encourage you to look at our Day 1 Recap Video and Day 1 ACR Best Abstracts. Here are a few of my favorites from the first day.
Read Article
TNF inhibitors and radiographic progression in axSpA
A remaining challenge for clinicians is the ability to delay, if not completely stop, structural progression in patients with axSpA, whether they are diagnosed with radiographic (r-axSpa) or non-radiographic (nr-axSpA) disease.
Read Article
JAK Inhibitors in Refractory Adult and Childhood-Onset Still’s Disease
Still's disease is an autoinflammatory disease characterized by spiking fever, rash, polyarthralgia, sore throat and even life-threatening complications, such as macrophage activation syndrome. It was first described by George Still in the late 1800s.
Read Article
Rush on over to ‘DASH’ diet to ⬇️women at risk for gout abst#0991 #ACR21 @RheumNow it is low salt diet and ⤵️serum urate and HTN https://t.co/smQgVpV3BD
Janet Pope Janetbirdope ( View Tweet)
Image of Takayasu's retinopathy (compared to normal) presented by John Stone #ACR21 . I'm no eye doctor, but this cannot be good. @RheumNow https://t.co/rjoQZ8TGDz
Richard Conway RichardPAConway ( View Tweet)
⭐️C-OPTIMISE:
Early, active AxSpA on certilozumab (CZP) 200mg q2w x 48w. Then, if remission, randomized to CZP q2w vs q4w vs PBO x 48w
➡️No flare in PBO BUT w/ ↑:
*️⃣ASDAS + BASDAI
*️⃣CRP + fecal calprotectin
Thus, keep some dose of CZP on!
Abst#0916 #ACR21 @RheumNow https://t.co/DT8FKHAhr0
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
"Studying the pandemic is definitely impaired by the pandemic"...loved the quote! by @cappelliMD
Epi and Public health Abstract session I #ACR21 @RheumNow
Bella Mehta bella_mehta ( View Tweet)
⭐️Imaging of the SIJ in psoriatic axSpA is similar to axSpA associated with iritis or colitis!
Abst#0902 (https://t.co/f55Vfi1LSS)
#ACR21 @RheumNow https://t.co/UCXrwPiyhh
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
"Healthier moms lead to healthier babies. This is how I frame the discussion regarding medications and PsA in my practice (with regard to reproductive health)." Dr. Talabi #ACR21 @RheumNow #RheumNow
Dr. Rachel Tate uptoTate ( View Tweet)
How concerned should we be for #hydroxychloroquine retinopathy. >4000 pts prospectively followed. 1/2 w RA & 15% w #SLE. New risks Asian with pericentral pattern and overall. Length of time on use and ⬆️wt based dose per day & CKD all risks. Abst#0989 #ACR21 #ACRBest @RheumNow https://t.co/XTfdQpVC7H
Janet Pope Janetbirdope ( View Tweet)
In pts w/o RF, liver bx prev suggestd if lifetime cumulative MTX dose was 1-1.5g, then 3.5-4g.
All pts in centre offered Fibroscan
liver stifness associations:
- age, BMI
- not cumulative MTX dose
maybe survival bias, but what we're doing now is fine!
#ACR21 ABST0786 @RheumNow https://t.co/I6IhS3jhmC
David Liew drdavidliew ( View Tweet)
Aware of COPA syndrome?
➡️Rare cause of immune-mediated lung dz
➡️Mimics RA-ILD, SLE, & vasculitis
➡️Adult-onset cases reported
Abst#0529 determined that mutations in the COPA gene underlie some cases of severe pulmonary fibrosis.
#ACR21 @RheumNow https://t.co/mCx3eT7Pv8
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
📢Do not miss the #Lupus Faculty panel discussion @RheumNow on a selection of interesting abstracts presented on Day 2 📝#ACR21 @KDAO2011 @Janetbirdope @bella_mehta @_Castillo_Pedro @RHEUMarampa https://t.co/e0v4qQIE4h
Md Yuzaiful Md Yusof Yuz6Yusof ( View Tweet)
What to do if pt on a TNFi develops cancer? Can you safely restart TNFi later? Depends on cancer, timing - how long ago was cancer, Rx and patient preference. Data diff from RABBIT registry vs British bio registry @RheumNow #ACR21 #ACRBest 7S413 Have a look https://t.co/q9SFKlFJzg
Janet Pope Janetbirdope ( View Tweet)
Very interesting talks by Dr. Kim and Dr. Hyrich on DMARDs and Cancer risks
#ACR21 @RheumNow https://t.co/Dl5WPo7mmj
Akhil Sood MD AkhilSoodMD ( View Tweet)
This feels like an excellent starting point for Tuesday's ORAL Surveillance malignancy discussion.
RWE Cohort: HR 1.01 (0.83-1.22)
RCT-dup Cohort: HR 1.19 (0.86-1.64)
ORAL Surveillance: HR 1.48 (1.04-2.09)
Interesting day 4 ahead!
great talk @SeoyoungCKim #ACR21 7S413 @RheumNow https://t.co/YSau21goMr
David Liew drdavidliew ( View Tweet)
Does concomitant SJS affect tx effectiveness in RA?
Abst#0839 suggest yes!
➡️RA+SjS have an inferior response to TNFi than RA patients w/o SjS
BUT, RA/SJS pts w/ longer RA dz duration & ↑ DAS28 + HAQ-scores.
What's your clinical experience with this?
#ACR21 @Rheumnow https://t.co/TIc3raMOSJ
Meral K. El Ramahi, MD MeralElRamahiMD ( View Tweet)
If obvious dermatomyositis, you don’t need EMG for dx but may use for severity of involvement or if failing Rx or r/o steroid myopathy. For ?polymyositis ALWAYS do bx and often do EMG as broad differential #ACR21 @RheumNow https://t.co/L1xu3OuRYJ
Janet Pope Janetbirdope ( View Tweet)
RheumNow’s expanded coverage of #ACR21 is sponsored in part by @bmsnews, @JanssenUS, @Novartis. All content chosen by RheumNow & its Faculty.
Dr. John Cush RheumNow ( View Tweet)
A worthwhile point:
despite historic concerns, in the modern era TNFi can used safely & well in HIV pts
18y follow-up, all pts high CD4
(their starting criteria: CD4>200, VL <60,000)
no reported opportunistic infx
good arthritis response
#ACR21 ABST0965 @RheumNow @CCalabreseDO https://t.co/5pbRg63ubr
David Liew drdavidliew ( View Tweet)